ArticleCirculation reports2025
Effects of Nitric Oxide on Hemodynamics After Transcatheter Mitral Valve Repair Complicated by Pulmonary Hypertension - A Study Protocol.
Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated pulmonary arterial pressure (PAP) is associated with poor prognosis in patients with functional mitral regurgitation (MR) undergoing transcatheter mitral valve repair (TMVr). Nitric oxide (NO) inhalation therapy reduces PAP and pulmonary vascular resistance (PVR) after open-heart surgery, but its efficacy in patients with pulmonary hypertension (PH) undergoing catheter intervention remains unclear. Methods and Results: This open-label, interventional, randomized controlled trial will investigate the efficacy of NO inhalation therapy after TMVr for MR complicated by PH. A total of 40 patients aged ≥18 years diagnosed with PH (mean PAP >20 mmHg) during preoperative right heart catheterization and scheduled for TMVr for MR are included in this study. Patients receiving pulmonary vasodilators, with NO contraindications, and with unstable conditions requiring intravenous catecholamines or mechanical circulatory support devices are excluded. Eligible patients are randomly allocated to the NO inhalation or control group in a 1 : 1 ratio. NO (20 ppm) is administered post-TMVr (D0) until the day after TMVr (D1). The control group is administered oxygen as necessary. The primary endpoint is the change in PVR (baseline to D1). The secondary endpoints include changes in cardiac index and mean PAP (baseline to D1), changes in PVR immediately before NO administration post-TMVr to D1, and postoperative complication rates. Conclusions: This study will assess the efficacy of NO inhalation in patients with PH undergoing TMVr for MR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.